TrueBody vs Hims for GLP-1: New vs Established Platform

TrueBody represents a newer entrant in the GLP-1 telehealth space, while Hims has established itself as a major player in men's health and weight management. Both platforms offer semaglutide for weight loss, but they differ significantly in pricing, medication selection, and overall approach to patient care.

This comparison targets patients who want to understand the trade-offs between a specialized newcomer and an established telehealth giant. We'll examine pricing structures, medication availability, doctor oversight quality, patient experience, and long-term value to help you make an informed decision about your GLP-1 therapy.

Quick Verdict: Which Platform Wins?

TrueBody: What You Get

TrueBody launched in 2023 as a specialized weight management platform focusing exclusively on GLP-1 medications. Unlike broader telehealth companies, TrueBody positions itself as a boutique service with personalized care and access to both first-generation and newer GLP-1 therapies.

The platform's pricing structure starts at $297 per month for semaglutide therapy, which includes the medication, physician consultation, and ongoing monitoring. Tirzepatide, their premium offering, costs $397 per month. These prices reflect TrueBody's positioning as a premium service rather than a budget option.

TrueBody's consultation process involves a comprehensive health assessment followed by a video call with a licensed physician. The initial consultation typically lasts 20-30 minutes and covers medical history, current medications, weight loss goals, and lifestyle factors. Patients receive a personalized treatment plan that includes dosing schedules, dietary recommendations, and follow-up protocols.

The platform ships medications within 3-7 business days using temperature-controlled packaging to maintain medication integrity. All prescriptions come with detailed injection instructions, disposal supplies, and access to TrueBody's patient support team for technical questions about administration.

Monthly follow-ups are conducted via secure messaging or video calls, with physicians monitoring weight loss progress, side effects, and dose adjustments. TrueBody emphasizes gradual dose escalation to minimize gastrointestinal side effects, following clinical protocols established in major semaglutide and tirzepatide trials.

TrueBody Pros:

• Access to both semaglutide and tirzepatide
• Specialized focus on GLP-1 therapy
• Direct physician oversight with longer consultation times
• Personalized dosing protocols
• Temperature-controlled medication shipping

TrueBody Cons:

• Higher pricing compared to established competitors
• Limited track record as a newer platform
• Slower shipping times
• No insurance coverage options
• Smaller patient support infrastructure

Hims: What You Get

Hims entered the weight management space in 2022, using its established telehealth infrastructure built for men's health products. The company has since expanded to serve all genders and now represents one of the largest GLP-1 telehealth providers by patient volume.

Hims offers semaglutide starting at $199 per month for their basic plan, which includes a 1mg dose with physician oversight and monthly check-ins. Their premium plan costs $399 per month and includes higher doses, priority support, and additional lifestyle coaching resources.

The Hims consultation process is simplified for efficiency. Patients complete an online health questionnaire that takes approximately 10-15 minutes, followed by a brief consultation with a licensed healthcare provider. The entire process from signup to prescription approval typically takes 24-48 hours.

Medication shipping occurs within 2-3 business days through Hims' established logistics network. The company uses partnerships with major shipping carriers to ensure reliable delivery and has invested heavily in packaging technology to maintain medication stability during transport.

Hims provides ongoing support through their mobile app, which includes weight tracking, side effect monitoring, and direct messaging with healthcare providers. The platform also offers optional add-on services like nutritionist consultations and fitness coaching for an additional monthly fee.

The company's scale advantages become apparent in their customer service infrastructure. Hims maintains 24/7 patient support lines, extensive FAQ resources, and a strong online community where patients share experiences and tips for managing GLP-1 therapy.

Hims Pros:

• Competitive pricing with multiple plan options
• Established telehealth infrastructure and reliability
• Fast shipping and order processing
• Comprehensive mobile app with tracking features
• 24/7 customer support availability
• Optional lifestyle coaching add-ons

Hims Cons:

• Limited to semaglutide only
• Shorter consultation times with providers
• Less specialized focus on GLP-1 therapy
• Higher patient-to-provider ratios
• Limited personalization in treatment protocols

Price Comparison: TrueBody vs Hims

The pricing difference between these platforms reflects their distinct positioning strategies. Hims targets price-conscious consumers with their $199 starting price, while TrueBody's $297 minimum positions them as a premium service.

However, direct price comparisons can be misleading. Hims' $199 plan includes 1mg semaglutide doses, which may be insufficient for patients requiring higher therapeutic doses. Their $399 premium plan provides doses up to 2.4mg, matching the maximum FDA-approved dose for weight management.

TrueBody's single pricing tier includes flexible dosing from 0.25mg to 2.4mg based on individual response and tolerance. This approach eliminates the need to upgrade plans as doses increase, potentially offering better long-term value for patients who require higher doses.

The cost difference becomes more significant when considering TrueBody's tirzepatide option at $397 per month. Tirzepatide has demonstrated superior weight loss outcomes in head-to-head trials against semaglutide, with patients losing an average of 15-20% of body weight compared to 10-15% with semaglutide (Jastreboff et al., NEJM, 2022).

Neither platform accepts insurance coverage, requiring patients to pay out-of-pocket. This cash-pay model allows both companies to offer simplified service without insurance bureaucracy but creates a significant monthly expense for most patients.

When calculating total treatment costs, consider that most patients require 6-12 months of therapy to achieve significant weight loss. A patient choosing Hims' basic plan would spend $1,194-$2,388 over this period, while TrueBody's semaglutide option costs $1,782-$3,564 for the same duration.

Medication Options: TrueBody vs Hims

The medication selection represents the most significant difference between these platforms. TrueBody offers both semaglutide and tirzepatide, while Hims provides semaglutide exclusively. This distinction has important clinical implications for treatment effectiveness and patient outcomes.

Semaglutide, available on both platforms, is a GLP-1 receptor agonist approved by the FDA in 2021 for chronic weight management. Clinical trials demonstrate average weight loss of 10-15% of body weight over 68 weeks when combined with lifestyle modifications (Wilding et al., NEJM, 2021).

Tirzepatide, exclusive to TrueBody among these two options, represents a newer dual-action medication targeting both GLP-1 and GIP receptors. The SURMOUNT-1 trial showed superior weight loss outcomes, with patients losing up to 22.5% of body weight at the highest dose (Jastreboff et al., NEJM, 2022).

Both medications require subcutaneous injection once weekly, but tirzepatide's dual mechanism of action provides enhanced glucose control and appetite suppression. This translates to potentially greater weight loss for patients who can tolerate the medication and afford the higher cost.

TrueBody's access to both medications allows physicians to tailor treatment based on individual patient factors, medical history, and treatment goals. Patients who don't respond adequately to semaglutide can transition to tirzepatide without changing platforms.

Hims' focus on semaglutide reflects a strategic decision to offer the most established GLP-1 option at competitive pricing. While this limits treatment options, semaglutide remains highly effective for most patients and has a longer track record of clinical use.

Doctor Quality and Oversight

Both platforms employ licensed healthcare providers, but their approaches to patient care differ significantly in depth and specialization. TrueBody emphasizes specialized GLP-1 expertise, while Hims uses a broader network of general practitioners and nurse practitioners.

TrueBody's physicians undergo specific training in GLP-1 therapy, including protocols for dose escalation, side effect management, and patient selection criteria. The platform's consultation times average 20-30 minutes, allowing for comprehensive discussion of treatment goals, potential side effects, and lifestyle modifications.

Hims utilizes a network of licensed healthcare providers including physicians, nurse practitioners, and physician assistants. While all providers are qualified to prescribe GLP-1 medications, their background may vary in weight management specialization. Consultation times are typically shorter, averaging 10-15 minutes per interaction.

The follow-up care models also differ substantially. TrueBody schedules monthly video consultations with the same physician when possible, creating continuity of care and allowing providers to track progress over time. Patients can also access their physician through secure messaging for questions between appointments.

Hims provides follow-up care primarily through their mobile app and messaging system. While patients can request phone or video calls with providers, the default model relies on asynchronous communication and standardized check-in questionnaires.

Both platforms maintain appropriate medical oversight for GLP-1 therapy, including contraindication screening, drug interaction checks, and monitoring for adverse effects. The choice between them often comes down to preference for personalized attention versus simplified efficiency.

Patient Experience and Reviews

Patient satisfaction data reveals distinct patterns between these platforms, reflecting their different service philosophies and target demographics. TrueBody patients frequently cite personalized care and medication options as key advantages, while Hims users appreciate convenience and cost-effectiveness.

TrueBody maintains an average rating of 4.2/5 stars across review platforms, with patients praising the thorough consultation process and physician accessibility. Common positive feedback includes appreciation for tirzepatide availability and detailed side effect management guidance.

However, some TrueBody patients report concerns about higher costs and longer shipping times compared to competitors. A few reviews mention difficulty reaching customer service outside business hours, reflecting the company's smaller support infrastructure.

Hims averages 4.0/5 stars in patient reviews, with high marks for convenience, fast shipping, and mobile app functionality. Patients frequently mention the simplified signup process and competitive pricing as primary reasons for choosing the platform.

Criticism of Hims typically focuses on shorter consultation times and less personalized care. Some patients report feeling rushed during provider interactions or receiving generic responses to specific questions about side effects or dosing concerns.

Both platforms maintain good safety records with appropriate adverse event reporting to the FDA. Neither has faced significant regulatory actions related to their GLP-1 prescribing practices, indicating compliance with telehealth standards and medication safety protocols.

Response times for customer service inquiries average 2-4 hours for TrueBody and 1-2 hours for Hims during business hours. Both companies provide after-hours support for urgent medical questions, though Hims offers more comprehensive 24/7 availability.

Which Is Right for You?

The choice between TrueBody and Hims depends on your priorities, budget, and specific treatment needs. Each platform serves different patient profiles effectively, and understanding these distinctions helps guide the decision-making process.

Choose TrueBody if you: Want access to tirzepatide, prefer longer consultation times with specialized physicians, value personalized treatment protocols, and can afford higher monthly costs. TrueBody suits patients who view GLP-1 therapy as a significant medical intervention requiring specialized expertise.

Choose Hims if you: Prioritize cost-effectiveness, prefer simplified service delivery, want fast shipping and comprehensive app features, and are satisfied with semaglutide as your treatment option. Hims works well for patients who want efficient access to proven GLP-1 therapy without extensive personalization.

Patients with complex medical histories, multiple medications, or previous GLP-1 experience may benefit from TrueBody's more specialized approach. Those seeking their first weight loss medication or preferring a straightforward, cost-effective solution might find Hims more suitable.

Consider also that FormBlends offers physician-supervised GLP-1 therapy with compounded semaglutide and tirzepatide options at competitive pricing. Our clinical team provides personalized dosing protocols and comprehensive patient support throughout your weight loss process.

Frequently Asked Questions

Do TrueBody and Hims accept insurance for GLP-1 medications?

Neither TrueBody nor Hims accepts insurance coverage for their GLP-1 weight loss programs. Both operate on a cash-pay model, requiring patients to pay monthly subscription fees that include medication costs, physician consultations, and ongoing support services.

How long does it take to see weight loss results with these platforms?

Most patients begin seeing weight loss within 4-8 weeks of starting GLP-1 therapy through either platform. Significant weight loss typically occurs over 3-6 months, with maximum effects reached after 6-12 months of consistent treatment. Individual results vary based on starting weight, adherence to lifestyle modifications, and medication tolerance.

Can I switch between TrueBody and Hims if I'm not satisfied?

Yes, patients can switch between platforms, though this requires starting a new consultation process with the chosen provider. Both companies allow patients to cancel subscriptions with 30 days notice. When switching, ensure continuity of medication supply to avoid treatment interruption.

What happens if I experience side effects with either platform?

Both TrueBody and Hims provide medical support for side effect management. TrueBody offers direct physician access through video calls and messaging, while Hims provides support through their app and provider network. Common side effects like nausea, vomiting, and diarrhea can often be managed with dose adjustments or timing modifications.

Do these platforms offer any guarantees for weight loss results?

Neither TrueBody nor Hims guarantees specific weight loss outcomes, as individual results vary significantly based on multiple factors including genetics, lifestyle adherence, and underlying medical conditions. Both platforms focus on providing appropriate medical oversight and evidence-based treatment protocols rather than promising specific results.

Ready to Start Your Weight Loss Goals?

Choosing between TrueBody and Hims represents just one option in the expanding GLP-1 telehealth market. Both platforms offer legitimate pathways to accessing these effective weight loss medications, each with distinct advantages depending on your specific needs and preferences.

If you're looking for an alternative that combines specialized physician oversight with competitive pricing, consider FormBlends' comprehensive weight management program. Our clinical team provides personalized GLP-1 therapy with both semaglutide and tirzepatide options, supported by ongoing medical supervision and patient education.

Remember that successful weight loss with GLP-1 medications requires more than just prescription access. Choose a platform that provides the level of medical support, medication options, and ongoing guidance that matches your individual health goals and treatment preferences.

Sources

• Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216.
• Wilding, J.P., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.
• TrueBody official website pricing and service information. Accessed March 13, 2026.
• Hims & Hers official website pricing and medication details. Accessed March 13, 2026.
• FDA prescribing information for semaglutide (Wegovy) and tirzepatide (Zepbound). FDA.gov, 2024.
• Patient review data aggregated from Trustpilot, Google Reviews, and Better Business Bureau ratings. Accessed March 2026.